Tracer library / [161Tb]Tb-PSMA-617
[161Tb]Tb-PSMA-617
Also written as PSMA-617; Pluvicto
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- PSMA-targeted radioligand (PSMA-617 conjugate labeled with terbium-161)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 42709069
- Clinical application
- Metastatic castration-resistant prostate cancer (mCRPC) PMID 42709069
- Theranostic pair
- [111In]In-PSMA-617
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Validation of Manual In-House Synthesis, Imaging, Biodistribution, and Dosimetry of Tb-161 PSMA-617 for mCRPC Patients in a Tertiary Health Care Center: A Proof-of-Concept Study.2026 · Cancer Biother Radiopharm · Clinical study
Need this precursor?We can point you to suppliers for [161Tb]Tb-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.